What is Aidoc's First Read tool?

**First Read** is a generative AI tool from Aidoc that drafts radiology reports for radiologists to review. It builds on Aidoc's clinically validated CARE™ foundation model. The FDA granted it Breakthrough Device Designation on June 25, 2026, specifically for detecting and describing four life-threatening findings on chest X-rays, helping radiologists manage rising imaging demand.

What does FDA Breakthrough Device Designation mean for a radiology AI tool?

The FDA's Breakthrough Device Designation is a pathway designed to speed up the review of devices that provide more effective diagnosis or treatment of serious conditions. For generative AI radiology tools like First Read and Cognita, it signals FDA engagement with a technology that challenges traditional validation and regulatory frameworks, according to STAT News reporting from June 25, 2026.

How is generative AI in radiology different from older AI tools?

Older machine learning systems analyzed images like X-rays and CT scans and highlighted specific spots for a radiologist to review and write up manually. Generative AI tools, using large vision language models, can process the entire image and draft many of the findings directly. A radiologist then reviews the AI-generated draft rather than writing the report from scratch.

What is Cognita and how does it relate to Aidoc's announcement?

**Cognita** is a generative AI radiology tool founded by Stanford researchers and acquired late last year by Radiology Partners, a large radiology practice. It received FDA Breakthrough Device Designation in March 2026. Aidoc's First Read received a separate designation in June 2026, making the two tools the first generative AI radiology products to earn this FDA status in 2026.

How many hospitals does Aidoc currently support?

Aidoc supports diagnostic decisions across nearly 2,000 hospitals worldwide, according to the company's announcement on June 25, 2026. Its platform is designed to integrate into a facility's existing IT infrastructure, enabling AI deployment at scale across radiology and other clinical workflows.

FDA Grants Aidoc Radiology AI Breakthrough Status

By iCharles News · June 25, 2026

Bookmark

Aidoc's First Read tool earned FDA Breakthrough Device Designation for AI-drafted radiology reports, joining Cognita as the second such generative AI tool to receive the designation in 2026.

FDA Grants Aidoc Radiology AI Breakthrough Status

What did the FDA just approve for Aidoc?

The FDA granted Aidoc's First Read tool Breakthrough Device Designation on June 25, 2026. First Read is a generative AI tool that drafts radiology reports for radiologists to review. The designation applies specifically to four life-threatening findings that the tool can detect and describe. Aidoc announced the designation via PR Newswire on the same day.

Who is Aidoc?

Aidoc is a clinical AI company that supports diagnostic decisions across nearly 2,000 hospitals worldwide. Its platform integrates into existing hospital IT infrastructure. First Read extends Aidoc's clinically validated CARE™ foundation model into report drafting workflows.

How does First Read work?

Traditional machine learning tools flag spots on an X-ray or CT scan for a radiologist to review and write up manually. First Read works differently. It processes the entire image and drafts many of its findings directly. A radiologist then reviews the draft. This approach is built on Aidoc's CARE™ foundation model and is designed to help radiologists meet rising imaging demand.

Agility Digit: Live at Amazon, GXO & Toyota

Nvidia Banned Chips Double in Price on China

CAISI Signs AI Reviews With Google, Microsoft

Meta Smart Glasses Switch to Muse Spark AI

Is Aidoc the only company to get this designation?

No. As we read the reporting, two generative AI radiology tools have now received FDA Breakthrough Device Designation in 2026. STAT News reported that Cognita received the first designation in March 2026. Aidoc's First Read received the second designation in June 2026.

What is Cognita?

Cognita is a generative AI radiology tool founded by Stanford researchers. It was acquired late last year by Radiology Partners, a large radiology practice. Its breakthrough designation came in March 2026, roughly three months before Aidoc's.

How do the two designations compare?

Detail	Cognita	Aidoc First Read
Company	Cognita / Radiology Partners	Aidoc
Founders	Stanford researchers	—
Designation date	March 2026	June 25, 2026
Scope reported	Chest X-ray interpretation, report drafting	Four life-threatening findings on chest X-rays
Hospital reach	—	Nearly 2,000 hospitals

Why does this regulatory designation matter?

The FDA's Breakthrough Device Designation is intended to speed up the review of devices that provide more effective treatment or diagnosis of serious conditions. Generative AI in radiology presents new challenges for traditional validation and regulatory frameworks, according to STAT News. Large vision language models can now process an entire image and draft findings — a capability that goes beyond older machine learning tools that only highlighted areas for human review.

For builders tracking Perplexity CEO hybrid AI developments and similar AI infrastructure stories, the regulatory path for clinical generative AI is worth watching closely.

What findings does First Read target?

Aidoc's First Read received its breakthrough designation specifically for detecting and describing four life-threatening findings. The sources do not name all four findings individually. The tool is designed to help radiologists handle rising imaging demand by drafting report content for those critical cases.

What is the CARE™ foundation model?

The CARE™ foundation model is Aidoc's clinically validated AI model. First Read extends this model into report drafting workflows. Aidoc describes it as the foundation for its clinical AI solutions across hospital settings.

Key facts at a glance:

Aidoc announced FDA Breakthrough Device Designation for First Read on June 25, 2026
First Read targets four life-threatening findings on chest X-rays
Aidoc operates across nearly 2,000 hospitals worldwide
Cognita (Radiology Partners) received the first generative AI radiology breakthrough designation in March 2026
Both tools use large vision language models to draft full radiology reports, not just flag findings

The most confirmed next step from the sources is Aidoc's continued pursuit of FDA clearance for First Read, with the Breakthrough Device Designation now in place to support that process.

Frequently asked questions

What is Aidoc's First Read tool?: **First Read** is a generative AI tool from Aidoc that drafts radiology reports for radiologists to review. It builds on Aidoc's clinically validated CARE™ foundation model. The FDA granted it Breakthrough Device Designation on June 25, 2026, specifically for detecting and describing four life-threatening findings on chest X-rays, helping radiologists manage rising imaging demand.
What does FDA Breakthrough Device Designation mean for a radiology AI tool?: The FDA's Breakthrough Device Designation is a pathway designed to speed up the review of devices that provide more effective diagnosis or treatment of serious conditions. For generative AI radiology tools like First Read and Cognita, it signals FDA engagement with a technology that challenges traditional validation and regulatory frameworks, according to STAT News reporting from June 25, 2026.
How is generative AI in radiology different from older AI tools?: Older machine learning systems analyzed images like X-rays and CT scans and highlighted specific spots for a radiologist to review and write up manually. Generative AI tools, using large vision language models, can process the entire image and draft many of the findings directly. A radiologist then reviews the AI-generated draft rather than writing the report from scratch.
What is Cognita and how does it relate to Aidoc's announcement?: **Cognita** is a generative AI radiology tool founded by Stanford researchers and acquired late last year by Radiology Partners, a large radiology practice. It received FDA Breakthrough Device Designation in March 2026. Aidoc's First Read received a separate designation in June 2026, making the two tools the first generative AI radiology products to earn this FDA status in 2026.
How many hospitals does Aidoc currently support?: Aidoc supports diagnostic decisions across nearly 2,000 hospitals worldwide, according to the company's announcement on June 25, 2026. Its platform is designed to integrate into a facility's existing IT infrastructure, enabling AI deployment at scale across radiology and other clinical workflows.

Sources

announced the designation prnewswire.com
STAT News reported statnews.com

Keep reading

ShinyHunters Exploits Oracle PeopleSoft Zero-Day

Tencent WeCom Launches DeepSeek V4 AI Agent

Apple-Intel Chip Deal: Production Still Years

Anthropic Accuses Alibaba of 28.8M-Exchange AI